Should you invest in Judges Scientific plc, up 5% today?

This is why I think there is much more to come for investors from Judges Scientific plc (LON: JDG).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

I’m so used to share prices falling on the day a company announces its results that it is refreshing to see Judges Scientific (LSE: JDG) go up today on the release of its interims.

I think we can find the reason for the move in Chairman Alex Hambro’s statement regarding the outlook. Today’s figures sparkle, and he told us that the strong operational momentum continued into the second half of the year. He and the other directors expect earnings per share for the full year to be “ahead of current market expectations.”Ah! Those magical words so beloved of private investors and investing institutions across the length and breadth of the land.

Good progress

It’s been a year since I last wrote about the firm and progress since then has been stonking. I said back then that the business had “staged quite a comeback from the doldrums it found itself in 12 months ago.” Indeed, over a 12-month period, the stock had surged around 53% higher based on a strong recovery in earnings. I’m happy to report today that the firm has repeated the trick with the shares moving another 37% higher over the past year on the back of earnings that are exploding higher.

The strategy of acquiring and developing scientific instrument businesses is paying off. In the first half of the year, revenue moved 13% higher, cash from operations shot up 43% and adjusted earnings per share rocketed 52% higher. Once again, the firm’s growth is well balanced with cash inflow supporting advances in earnings. And it’s not all down to the firm’s acquisition activity either. The organic order book moved 2.3% higher and organic revenue made up 5.7% of the overall revenue advance.

It seems clear that Judges Scientific is doing many things right, and it finds its reward in a cash balance that is 35% higher than it was six months ago, at £14.4m, and in a net debt figure that has plunged 68% since Christmas down to just £2.4m. The firm admits that an “underlying favourable foreign exchange environment”  boosted profits, but the balance sheet is sound and I reckon that bodes well for the future.

A positive outlook

Looking forward, Alex Hambro said in today’s report that demand in the short term will likely be affected by currency fluctuations and “the ups and downs of government spending in various parts of the global market.” However, he asserts that there is a long-term positive trend driving the scientific sector. To me, that outlook statement suggests a potential opportunity for investors. If you are focused on a long-term investing horizon, I reckon Judges Scientific has proved its mettle and any short-term weakness in the share price because of a slip in earnings can be viewed as an opportunity to buy some shares at a better price. You only have to look back as far as 2016 to see how well such a strategy would have worked out recently. I think the firm is one to keep a close eye on.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended Judges Scientific. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »